Aurinia Pharmaceuticals logo

Aurinia PharmaceuticalsNASDAQ: AUPH

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

03 September 2014

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.05 B
-75%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector
-79%vs. 3y high
69%vs. sector
-92%vs. 3y high
61%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:35:50 GMT
$7.35+$0.14(+1.93%)

Dividend

No data over the past 3 years
$57.19 M$57.69 M
$57.19 M$722.00 K

Analysts recommendations

Institutional Ownership

AUPH Latest News

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
businesswire.com11 October 2024 Sentiment: POSITIVE

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at ASN Kidney Week 2024.

Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
seekingalpha.com19 September 2024 Sentiment: POSITIVE

Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets. AUR200, now in Phase 1 trials, could be a significant future value driver targeting autoimmune diseases.

Aurinia Pharmaceuticals: This Recovery Can Continue
seekingalpha.com18 September 2024 Sentiment: POSITIVE

Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. AUPH is developing AUR200, with a phase 1 trial underway allowing it to diversify beyond Lupkynis. The Company reported a $722K net income for Q2'24, up from a $10.7M net loss in Q1'24.

Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript
seekingalpha.com01 August 2024 Sentiment: NEUTRAL

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Joseph Schwartz - Leerink Partners Stacy Ku - TD Cowen Ed Arce - H.C. Wainwright & Co. Operator Good day, ladies and gentlemen.

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
businesswire.com19 July 2024 Sentiment: POSITIVE

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024.

Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
zacks.com12 July 2024 Sentiment: NEUTRAL

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aurinia to Participate in Upcoming Investor Healthcare Conferences
businesswire.com02 July 2024 Sentiment: POSITIVE

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Upcoming Investor Healthcare Conferences.

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
zacks.com17 June 2024 Sentiment: POSITIVE

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
businesswire.com05 June 2024 Sentiment: POSITIVE

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with act.

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
businesswire.com04 June 2024 Sentiment: NEGATIVE

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce.

  • 1(current)
  • 2

What type of business is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

What sector is Aurinia Pharmaceuticals in?

Aurinia Pharmaceuticals is in the Healthcare sector

What industry is Aurinia Pharmaceuticals in?

Aurinia Pharmaceuticals is in the Biotechnology industry

What country is Aurinia Pharmaceuticals from?

Aurinia Pharmaceuticals is headquartered in Canada

When did Aurinia Pharmaceuticals go public?

Aurinia Pharmaceuticals initial public offering (IPO) was on 03 September 2014

What is Aurinia Pharmaceuticals website?

https://www.auriniapharma.com

Is Aurinia Pharmaceuticals in the S&P 500?

No, Aurinia Pharmaceuticals is not included in the S&P 500 index

Is Aurinia Pharmaceuticals in the NASDAQ 100?

No, Aurinia Pharmaceuticals is not included in the NASDAQ 100 index

Is Aurinia Pharmaceuticals in the Dow Jones?

No, Aurinia Pharmaceuticals is not included in the Dow Jones index

When was Aurinia Pharmaceuticals the previous earnings report?

No data

When does Aurinia Pharmaceuticals earnings report?

The next expected earnings date for Aurinia Pharmaceuticals is 07 November 2024